80 likes | 188 Views
EMCC ECCO ESMO 2011 GI CancerUpdates RESPECT Phase IIb Study. Author: J Tabernero et al Reviewed by: Dr. Scott Berry Date posted: October 20, 2011.
E N D
EMCC ECCO ESMO 2011 GI CancerUpdates RESPECT Phase IIb Study Author: J Tabernero et al Reviewed by: Dr. Scott Berry Date posted: October 20, 2011
A Phase 2b, Double-Blind, Randomized Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared With Placebo (PBO) When Administered in Combination With Chemotherapy (Modified FOLFOX6) for First-line Treatment (tx) of Patients (Pts) With Metastatic Colorectal Cancer (mCRC). The RESPECT Trial Author: J Tabernero et al
Study Design N=200 Primary Outcome: PFS Sorafenib 400 mg po BID + mFOLFOX6 R Placebo +mFOLFOX6 Untreated Metastatic Colorectal Cancer ECOG 0/1
STUDY COMMENTARY • The excess toxicity seen in the sorafenib arm had a major impact on the delivery of chemo in that arm • Sorafenib arm – no improvement in PFS, reduced RR and more toxic
BOTTOM LINE FOR MEDICAL ONCOLOGISTS • Another VEGF TKI (along with PTK787, sunitininb and cediranib) that has failed to make an impact in the treatment of mCRC